{"content":[{"text":"“We are honored to be recognized for our dedication and efforts to bring a \n novel treatment option to the clinic for those with CDD and other rare \n epilepsies,” said Amit Rakhit, M.D., MBA, chief medical and portfolio \n management officer of Ovid Therapeutics. “It was important to everyone at \n Ovid that I travel to London to accept this award to show our unwavering \n support and partnership with the CDD community. We thank LouLou \n Foundation and the community and look forward to providing updates on our \n progress with the ARCADE study.” \n The CDKL5 Forum is a unique community of collaboration and knowledge \n exchange, made up of leading scientists, clinicians and company \n representatives from around the world, united in the mission of better \n understanding the CDKL5 gene and disorder. The objective is to share current \n research on CDKL5 and to stimulate peer-group discussion and brainstorming \n around existing and future avenues of research and therapeutic approaches, \n in order to accelerate treatments and ultimately find cures for this neuro- \n genetic disorder. Now in its fourth year, the Forum represents the flagship \n annual event of the CDKL5 Program of Excellence, established by the Loulou \n Foundation and the Orphan Disease Center of the University of \n Pennsylvania’s Perelman School of Medicine. \n About the ARCADE Trial \n ARCADE is a Phase 2, multi-center, open-label, pilot study that will evaluate \n the treatment of OV935 in pediatric patients, aged 2 to 17 years old, with \n epileptic seizures associated with CDD or Dup15q syndrome. The primary \n endpoint is the change in motor seizure frequency in patients treated with \n OV935 by disorder (CDD and Dup15q). The key secondary endpoints include \n safety and tolerability, including percentage of participants considered \n treatment responders, change in CGI-S/C and correlation of OV935 \n concentration and plasma 24HC levels. \n ARCADE is expected to enroll approximately 15 children with each condition \n at clinical trial sites in the United States. This study consists of a four to six \n week screening period to establish baseline seizure frequency followed by a \n 12-week treatment period (2-week dose titration and 10-week maintenance \n period.) To learn more about ARCADE \n visit clinicaltrials.gov or www.arcadestudy.com. At the end of treatment, \n eligible patients can roll over into the ENDYMION study. Additional details on \n the ENDYMION clinical trial can be found at www.clinicaltrials.gov. \n About Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder \n (CDD)","bbox":{"left":0.117686,"top":0.088287,"width":0.7640230000000001,"height":0.8057270000000001}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}